Effect of chronic naltrexone administration and its withdrawal on the regional activity of neurons that contain norepinephrine, dopamine and serotonin

A method is described that permits the simultaneous quantitation of norepinephrine (NE), dopamine (DA) serotonin (5-HT) and their respective major metabolites, 3-methoxy-4-hydroxy phenylglycol (MHPG), 3-methoxytyramine (3-MT), dihydroxyphenyl acetic acid (DOPAC) and 5-hydroxyindole acetic acid (5-HIAA) in discrete brain regions. The ratio of MHPG/NE, DOPAC/DA and 5-HIAA/5-HT was used to assess the effects of the chronic administration of the narcotic antagonist, naltrexone, and its withdrawal on the regional activity of neurons that contain NE, DA and 5-HT respectively. Chronic administration of naltrexone (8 days) is associated with a significant increase in the ratio of 5-HIAA/5-HT and DOPAC/DA in the frontal cortex and dorsal hippocampus respectively. Under this condition the thalamic concentration of 3-MT in 4 of 8 animals is also significantly elevated. In contrast, the mesolimbic forebrain exhibited a decrease in the MHPG/NE ratio (4 out of 8 animals). One day following naltrexone pellet removal the above ratios, as well as the mean content of 3-MT in the thalamus, returned to control values. At this time the content of 3-MT in the thalamus (5 of 5 animals) and frontal cortex (3 of 9 rats) was appreciably elevated, while its content in the dorsal hippocampus was significantly reduced (6 of 9 rats). These data suggest that the activity of several central monoaminergic neuronal systems are regulated by an opioid input that is tonically active.     

Enhanced norepinephrine output during long-term desipramine treatment: a possible role for the extraneuronal monoamine transporter (SLC22A3)

To study the delay (2-6 weeks) between initial administration of norepinephrine reuptake inhibitor antidepressants and onset of clinical antidepressant action, we examined the effects of desipramine treatment on urinary and plasma catecholamines and their metabolites during the initial 6 weeks of treatment in depressed patients. Catecholamines and metabolites in 24-h urine collections and 8:00 a.m. plasma samples were measured at baseline and after 1, 4, and 6 weeks of desipramine treatment. Desipramine treatment produced significant increases in urinary norepinephrine (NE) and normetanephrine (NMN) and plasma NE at Weeks 4 and 6, but not at Week 1. The ratio of urinary NE/NMN was increased at Weeks 4 and 6, suggesting a reduction in the metabolism of NE to NMN at extraneuronal sites by Weeks 4 and 6. The increases in urinary NE and NMN and plasma NE at Weeks 4 and 6 of desipramine treatment were associated with a reduction in the conversion of NE to NMN. This would be compatible with a blockade of the extraneuronal monoamine transporter (organic cation transporter 3; SLC22A3) by NMN. Inhibition of the extraneuronal monoamine transporter may be an important component in the clinical pharmacology of the norepinephrine reuptake inhibitor antidepressant drugs, such as desipramine.     

Differences in norepinephrine and dopamine neurotransmitter storage systems

Low doses of d-amphetamine (d-AMP) produced a 50% or greater decrease in the firing rates of both dopamine (DA) neurons (substantia nigra zone compacta) and norepinephrine (NE) neurons (locus coeruleus). However, pretreatment with the tyrosine hydroxylase inhibitor α-methyl-para-tyrosine (α-MT) blocked the d-AMP-induced reduction in DA neuron firing rate, but had no effect on the d-AMP-induced reduction in NE cell firing rate. Similarly, α-MT administered subsequent to d-AMP readily reversed the d-AMP-induced decrease in the firing rates of DA cells, but caused no significant reversal in NE cell firing rates. These electrophysiological findings, in conjunction with biochemical and behavioral data, support the hypothesis that there is a difference in the DA and NE neurotransmitter storage mechanism. In the DA neuron, there appears to be a slow transfer between stored and readily-releasable (newly synthesized) amine pools so that, following synthesis inhibition, there is little DA available for release. However, in the NE neuron, there is a more rapid mobilization of stored amine to readily releasable sites, such that d-AMP continues to cause the release of NE even though synthesis of transmitter is blocked.     

The effects of L-threo-3,4-dihydroxyphenylserine on the total norepinephrine and dopamine concentrations in the cerebrospinal fluid and freezing gait in parkinsonian patients

Summary We studied the effects of L-threo-DOPS (L-DOPS) on the concentrations of total (conjugated and unconjugated) dopamine (DA) and norepinephrine (NE) in the cerebrospinal fluid (CSF) of parkinsonian patients with freezing phenomenon. The NE concentration increased remarkably and dose-dependently after administration of L-DOPS in both L-dopa/carbidopa-pretreated and untreated patients. The DA concentration also increased mildly but significantly in L-dopa/carbidopa-untreated patients. Freezing phenomenon improved in 6 out of 8 patients at Hoehn and Yahr's stage III, and 1 out of 5 patients at stage IV. These results indicate that L-DOPS administration increases the NE concentration dosedependently, and is effective for freezing of gait of moderate severity.     

Measurement of tritiated norepinephrine metabolism in intact rat brain

A procedure for the study of NE metabolism in the intact rat brain is described. The method involves ventriculocisternal perfusion of the adult male rat with artificial CSF containing [³H]NE. Radioactivity in the perfusate associated with NE and its metabolites 3,4-dihydroxymandelic acid (DOMA), 3,4-dihydroxyphenylethyleneglycol (DHPG), 3-methoxy-4-hydroxymandelic acid (VMA), 3-methoxy-4-hydroxyphenylethyleneglycol (MHPG), and normetanephrine (NMN) is separated using high-performance liquid chromatography (HPLC). After 80 min the radioactivity in the perfusate reaches an apparent steady-state. Analysis of the steady-state samples shows higher activity in the fractions corresponding to DHPG and MHPG than in those corresponding to DOMA and VMA, confirming glycol formation as the major pathway of NE metabolism in rat brain. Pretreatment with an MAO inhibitor (tranylcypromine) results in a marked decrease in the deaminated metabolites DHPG and MHPG and a concurrent increase in NMN. The results indicate this to be a sensitive procedure for the in vivo determination of changes in NE metabolism.     

Regional depletion of central nervous system catecholamines: Effects on blood pressure and drinking behavior

The purpose of the present study was to identify which catecholamine-containing neurons (norepinephrine (NE) or dopamine (DA)) and which central nervous system (CNS) region(s) innervated by them might participate in the pressor and drinking responses produced by central drug stimulation. Forebrain NE was reduced in rats by injecting 4 micrograms of 6-hydroxydopamine (6-OHDA) into the ascending noradrenergic bundles. Spinal cord NE was depleted by intracisternal injection of 50 micrograms 6-OHDA. Depletion of forebrain DA was produced by bilateral injection of 4 micrograms 6-OHDA into the substantia nigra of desipramine-pretreated rats. Pressor responses to various doses of angiotensin II (AII), carbachol or hyperosmolar NaCl injected into the lateral ventricles (LVT); and drinking responses to LVT AII and carbachol were examined. Injection of 6-OHDA into the noradrenergic bundles reduced telencephalic and hypothalamic NE by more than 80% without significantly affecting brain DA or spinal cord NE. Intracisternal 6-OHDA depleted spinal cord NE by 80% and forebrain NE by 20-25% without reducing brain DA. Injection of 6-OHDA into the substantia nigra reduced telencephalic DA by 86% and NE by 29% without significantly affecting NE in other CNS regions. Substantia nigra 6-OHDA injected animals evidenced attenuated drinking to both LVT AII and carbachol. Pressor responses to LVT AII, carbachol and hypertonic saline were largely unaffected. Almost complete depletion of brain and/or spinal cord NE failed to alter centrally mediated drinking or pressor responses. These data indicate that the integrity of brain DA neurons is required for the behavioral but not hypertensive responses produced by central drug stimulation.     

Assessment of the effects of neonatal subcutaneous 6-hydroxydopamine on noradrenergic and dopaminergic innervation of the cerebral cortex

Female rats, treated at birth with 6-hydroxydopamine (3 x 100 mg/kg s.c. at 24 h intervals) or vehicle, were subjected at 112 days of age to unilateral electrolytic lesions of the locus coeruleus. Two weeks later regions of the telencephalon, both ipsi- and contralateral to the lesion, were simultaneously assayed for norepinephrine (NE) and dopamine (DA) content, and for tyrosine hydroxylase (TOH) and dopamine-beta-hydroxylase (DBH) activities. In the vehicle-treated rats the lesion resulted in at least an 80% reduction of NE and DBH on the ipsilateral side, relative to the contralateral side. TOH was reduced to a similar extent only in the parietal cortex and hippocampus. In the prefrontal cortex and cingulate gyrus TOH was decreased by only 31% and 64% respectively; the remainder was interpreted to be associated with projections of the mesocortical dopamine system. From this data it was possible to calculate that the ratio of TOH to DA in dopaminergic terminals is about 10-fold greater than the ratio of TOH to NE in noradrenergic terminals. Neonatal 6-hydroxydopamine treatment resulted in practically total elimination of noradrenergic terminals throughout the telencephalon, and the locus coeruleus lesion had no additional effect. The drug treatment produced no significant change in DA content or in the TOH to DA ratio in the prefrontal cortex and cingulate gyrus, indicating complete sparing of the mesocortical DA projections.     

Cross-sensitization between footshock stress and apomorphine on self-injurious behavior and neostriatal catecholamines in a rat model of Lesch–Nyhan syndrome

The effects of footshock sensitization (priming), apomorphine (APO) priming and their combination on behavior and neostriatal and cortical catecholamines were examined in adult rats which had neonatally received bilateral intracerebroventricular injections with 6-hydroxydopamine (6-OHDA; a model of Lesch–Nyhan syndrome (LNS)) or vehicle (unlesioned rats). Lesioned (6-OHDA-treated) rats displayed self-biting (SB; 7/20 rats) and self-injurious behavior (SIB; 1/20 rats) during APO priming, but not during footshock priming. During subsequent acute cumulative APO dosing, 20–30% of lesioned rats primed with APO alone or footshock alone displayed SB and SIB. However, SB and SIB incidence in APO+footshock-primed lesioned rats was nearly tripled. Dopamine (DA) synthesis, metabolism and extracellular concentrations (disposition) in unlesioned rats and in cortices of lesioned animals were unaffected by priming. In lesioned rats primed with APO alone or footshock alone, only neostriatal 3-methoxytyramine (3-MT) was significantly increased. However, neostriatal DA and metabolite concentrations (and norepinephrine (NE)) were all significantly elevated in lesioned rats primed with both APO and footshock. These results confirm that neonatal 6-OHDA-induced neostriatal catecholamine depletion can be antagonized by experiential change, suggest that behavioral and neurochemical cross-sensitization between APO and footshock in such rats is unidirectional and support the view that stress can exacerbate the incidence of SIB in LNS.     

Electrical activity of the hippocampus and neocortex in rats depleted of brain dopamine and norepinephrine: Relations to behavior and effects of atropine

Spontaneous behavior and cerebral electroencephalographic (EEG) activity were studied in rats depleted of the brain catecholamines dopamine (DA) and norepinephrine (NE) by intraventricular injections of 6-hydroxydopamine. It was found that there was a direct relation between the amount of DA depleted and degree of adipsia-aphagia, akinesia (lack of spontaneous activity), and sensorimotor neglect. Results from a number of tests as well as 24-h videorecordings showed that the rats with little or no central dopamine did not eat or drink, walk spontaneously, or orient to tactile stimulation, but they did initiate grooming as often as control rats. Video-recordings also showed that the DA-depleted rats made continuous postural adjustments, a behavior which may be similar to the akathisia or motor impatience described as a human Parkinson's disease symptom. EEG recordings revealed that both atropine-resistant (movement-related), and atropine-sensitive (immobility-related) forms of neocortical low-voltage, fast activity (LVFA) and hippocampal rhythmic slow activity (RSA or theta) survive depletion of brain DA and NE. Furthermore, the amplitude and frequency of theta activity were not changed by DA depletion. It is suggested that neither DA nor NE are critically important for the production of LVFA or RSA although DA may be indirectly involved in regulating the probability of their occurrence by regulating the probability of the occurrence of movement.     

Some factors affecting striatal 3-methoxytyramine concentrations in the mouse and rat

1. Apomorphine, a DA agonist, at a dose of 2 mg/kg, produced a rapid decline in 3-MT concentrations in the rat striatum; this is consistent with a reduction in the firing rate of nigrostriatal neurons.

2. The injection of a 12.5 mg/kg dose of phenylethylamine transiently increased 3-MT concentrations in the mouse striatum. A more profound increase was produced by this dose in the rat striatum.

3. Cocaine (5 mg/kg) produced a decrease in DOPAC concentrations in both species thus suggesting that the re-uptake of DA from the synaptic cleft in both species was very similar. Amfonelic acid, however, produced a different profile in each species.

4. The concentration of 3-MT is larger in the mouse striatum as a result of several possible mechanisms: the higher percentage of MAO isoenzyme B in the mouse brain (3-MT is a preferred substrate of MAO isoenzyme A) and/or due to differences in the clearance mechanisms for 3-MT produced extraneuronally — with the mouse having a less avid clearance system either for DA or for 3-MT.     

Effect of aging on dopamine metabolism in the rat cerebral cortex: a regional analysis

Summary Age-related changes in the levels of dopamine (DA) and its metabolites were measured in seven cerebral cortical areas and in the striatum of 3, 10 and 27 month-old Sprague-Dawley rats. An age-related increase in DA levels was observed in the somatomotor (SM) cortex. In contrast, a decrease was observed in the temporal (T) cortex. Decreases in homovanillic acid (HVA) levels were observed in prelimbic (PL), pyriform (PY) and T cortex of aged rats, whereas significant increases in the levels of 3-methoxytyramine (3-MT) were observed in PL, prefrontal (PF), cingulate (C) as well as in T cortex. In the striatum, DA and HVA were decreased but the level of 3-MT remained unchanged. Norepinephrine (NE) levels increased in rats from 3 to 27 months in all the cortical areas. The increase in the levels of the DA extraneuronal metabolite, 3-MT, confirms our previous results showing that the release of DA might be increased with age in some cortical areas. The present results show that there is no general age-related decrease in the level of monoamines and of their metabolites in the rat cerebral cortex and that the changes display a complex, area-specific pattern.     

Effect of dopamine, L-dopa, carbidopa and L-dopa/carbidopa on arthus and delayed hypersensitivity skin reactions in the rat

This study deals with the effects of dopamine (DA), L-dopa, carbidopa and L-dopa/carbidopa on immuno-inflammatory skin reactions in the rat. For this purpose, male Wistar rats immunized with bovine serum albumin in Freund's adjuvant were treated subcutaneously with different doses of DA, L-dopa, carbidopa and L-dopa/carbidopa, for a period of 14 consecutive days or 3 days before skin-testing with BSA. An additional group of rats received 1 injection of a dopamine-related drug 4 hours before and 1 injection 4 hours after skin-testing. Corresponding controls were treated with saline. Arthus and delayed hypersensitivity skin reactions were read at 4 and 24 hours respectively. The results showed that repeated injections of DA, L-dopa and L-dopa/carbidopa significantly suppressed Arthus and delayed reactions. The highest suppression was recorded in rats treated with L-dopa plus carbidopa. Concerning the dose required for immunosuppression it appears that DA was the most effective. Carbidopa did not affect hypersensitivity skin reactions. These results suggest the in vivo relationship between dopamine-related compounds (L-dopa and DA) and immuno-inflammatory reactions. Most probably, L-dopa when is given alone converts into DA and this increase of DA content in periphery depresses immune reactions. However, L-dopa given together with carbidopa (an enzyme which prevents decarboxylation of L-dopa into DA, and enables the penetration of L-dopa into CNS) augments the content of DA in the brain and thus affects immune responses. It appears, therefore, that L-dopa and DA act both peripherally and centrally on immune responsiveness.     

Dietary induced changes in catecholamine metabolites in rat urine

Summary The influence of dietary conditions on the excretion of catecholamine metabolites has been investigated in rats. Four groups of rats were nourished over several days, with the usual cereal rat chow (A) or a synthetic complete food (B) or 15% milk (C) or 12% sucrose solution (D),Interference from cereal-rich diet was observed on most metabolites: dopamine (DA), 3-0-methyldopamine (3-MT), 3, 4-dihydroxyphenylacetic acid (DOPAC), norepinephrine (NE) and epinephrine (E). The cerealinduced interference was the highest for conjugated DA metabolites.Sucrose diet suppressed the chemical dietary interferences on DA metabolites but induced sympathetic hyperactivity, together with sustained changes in lipid metabolism, as previously observed in sucrose overfeeding.Milk diet induced too catecholamine release but did not reduce dietary interference on DA and 3-MT.From these results, we conclude that the synthetic cereal-free meal B is convenient in studies including most catecholamine metabolites, except for conjugated DOPAC. In the latter case, sucrose diet proofs more appropriate, provided it is used over a short period.This work was supported from grants of CNRS (ER 96) and IFFA-CREDO.     

Region-specific alterations in the concentrations of catecholamines and indoleamines in the brains of young and old F344 rats after L-deprenyl treatment

The effects of L-deprenyl, a monoamine oxidase-B (MAO-B) inhibitor, on the concentrations of norepinephrine (NE), dopamine (DA), 3,4-dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA), serotonin (5-hydroxytryptamine), and 5-hydroxyindoleacetic acid (5-HIAA) in medial basal hypothalamus (MBH), substantia nigra (SN), striatum (Str), and nucleus accumbens (NAc) of young (3 month) and old (21 month) male F344 rats were examined after a 7-day wash-out period following 1, 15, or 30 days of deprenyl treatment in young rats and a 9-day wash-out period after a 10-week deprenyl treatment in old rats. The brain areas were microdissected and the concentrations of neurotransmitters were measured by High Performance liquid chromatography with electrochemical detection (HPLC-EC). Deprenyl administration following the drug wash-out period increased the concentrations of DOPAC in the SN, Str, and in the NAc of young rats but it was decreased in the NAc of old rats. The concentration of HVA was lower in the Str of young deprenyl-treated rats, and in the Str and NAc of old deprenyl-treated rats, but it was higher in the SN of young deprenyl-treated rats. The concentration of 5-HIAA was increased in the MBH, SN, and in the NAc of young deprenyl-treated rats, but it was decreased in the Str and NAc of old deprenyl-treated rats. The concentration of NE was increased in the MBH, SN, Str, and in the NAc of young rats treated with deprenyl and in the MBH of old deprenyl-treated rats. The concentration of 5-HT was increased in the SN of young deprenyl-treated rats. The concentration of DA increased in the Str of both young and old deprenyl-treated rats. We concluded that a drug wash-out period after deprenyl treatment differentially affects the metabolism of catecholamines and indoleamine depending on the region of the brain and that this effect may be due to variation in the kinetics of MAO inhibition.     

The effect of regional differences in noradrenergic neuron growth patterns on juvenile kindling

Kindling can be altered by a variety of lesions designed to deplete norepinephrine (NE). However, the effect of the regional alteration in NE concentration on seizure susceptibility has not been studied. Two different concentrations of 6-hydroxydopamine (6-OHDA) were administered to one-day-old rat pups. At age 18 days, rat with significant rostral brain NE loss, due to high dose 6-OHDA, had a faster rate of electrical kindling in the entorhinal cortex than controls. In contrast rats receiving low dose 6-OHDA which resulted in comparable forebrain NE depletion but with a dramatic hindbrain noradrenergic overgrowth showed no enhancement of kindling. These results suggest that in the immature rat the proconvulsant effect of forebrain NE depletion can be overridden by an augmentation of hindbrain NE growth patterns.     

Lack of effects of chlordecone on synthesis rates, steady state levels and metabolites of catecholamines in rat brain

Reports on effects of chlordecone on brain catecholamine concentrations have been inconsistent. Because various studies indicate the potential for toxic effects on neurotransmitter systems, the following study was performed to assess effects of chlordecone on brain adrenergic systems. Male Sprague-Dawley rats dosed once with chlordecone at 100 mg/kg were sacrificed after 24 hr, then brain norepinephrine (NE) and dopamine (DA) levels were assayed. Another group was fed chlordecone at 10 mg/kg for 10 days. Additionally, animals treated with 10 mg/kg/day were injected iv with 3H-tyrosine at two intervals prior to sacrifice in order to estimate NE and DA synthesis rates. Whole brain concentrations of NE, DA, 3,4-dihydroxyphenylacetic acid (DOPAC) and 3-methoxy-4-hydroxyphenylglycol sulfate (MOPEG-SO4) were measured. No changes were observed in whole brain catecholamine or metabolite concentrations, nor in NE or DA synthesis rates. In another experiment, administration of chlordecone (10 mg/kg for 10 days) was found not to alter the rate of incorporation of 3H-tyrosine into NE or DA in any brain area tested. Results suggest that the initial functional deficits responsible for neurological symptoms do not result from inhibition of synthesis and transport of brain catecholamines.     

Psychotic and nonpsychotic depressions: II. Platelet MAO activity, plasma catecholamines, cortisol, and specific symptoms

Preliminary data are presented on levels of plasma cortisol, dopamine (DA), epinephrine (EPI), and norepinephrine (NE) before and after dexamethasone in 22 depressed patients (of whom 4 were psychotic). Platelet monoamine oxidase (MAO) activity, determined in 19 of the depressed patients, was significantly higher in the 4 psychotic patients than it was in the 15 nonpsychotic patients. Positive correlations were observed before and after dexamethasone among cortisol, DA, EPI, and platelet MAO. After dexamethasone, plasma NE correlated negatively with DA, EPI, and cortisol. The various correlations were due largely to the inclusion of the psychotic depressive subgroup. Data are also presented on the relationships between these biological measures and specific signs and symptoms.     

Concentration of catecholamines and indoleamines in the cerebrospinal fluid of patients with vascular parkinsonism compared to Parkinson's disease patients

Summary The concentration of catecholamines and indoleamines in the cerebrospinal fluid of patients with vascular parkinsonism (VP) was compared to that in patients with Parkinson's disease (PD) and controls. Compared to the controls, the concentration of tyrosine was significantly higher, and the concentration of L-dopa and 3-O-methyldopa (3-OMD) was significantly lower in both VP and PD patients. The balance between the 3-OMD/L-dopa and dopamine (DA)/L-dopa ratios was changed in favor of 3-OMD/L-dopa in both VP patients and PD patients suggesting the preservation of a compensatory mechanism. All these changes were less marked in VP patients than in PD patients. A remarkable finding was that in contrast to PD patients the concentration of DA and norepinephrine (NE) was significantly higher in VP patients than in the controls. The decrease in the concentration of 5-hydroxytryptamine (5-HT) was significantly greater in VP patients than in PD patients. In PD patients, the concentration of DA, NE, and 5-HT showed significant correlation with the severity of motor symptoms. In VP patients, the concentration of 5-HT alone showed significant correlation with the severity of motor symptoms and cognitive dysfunction. These findings suggest that VP patients may have similar disturbances in the DA synthesis pathway as PD patients, but differ from PD patients in that the concentrations of DA and NE are elevated and the decrease in the 5-HT concentration is greater in VP patients.     

Microdialysates of amines and metabolites from core nucleus accumbens of freely moving rats are altered by dizocilpine

In vivo microdialysis combined with high performance liquid chromatography (HPLC) with electrochemical detection, was used to study the effect of MK-801 (0.1 mg/kg i.p.) on extracellular concentrations of dopamine (DA) 3,4-dihydroxyphenylacetic acid (DOPAC), serotonin (5-HT), norepinephrine (NE) and DOPAC/DA ratio in intact, 6-hydroxydopamine (6-OHDA)-lesioned, DSP4 (N-(2-chloroethyl)-N-ethyl-2-bromobenzyl-amine hydrochloride)-lesioned and reserpine-treated rats. The results revealed high basal DA (0.735+/-0.05 fmol/microl), DOPAC (195.93+/-20.18 fmol/microl) and NE (0.585+/-0.01 fmol/microl), low 5-HT (0.334+/-0.032 fmol/microl) and high DOPAC/DA ratio (265.11+/-20.73) in intact cACC. 6-OHDA alone (8 microg/2 microl) depleted DA (-66%), DOPAC (-65%), and NE (-62%). On the other hand, in desipramine (DMI)-pretreated rats, 6-OHDA induced a large depletion of DA (-94%), DOPAC (-97%) and reduced DOPAC/DA ratio (-73%), but increased NE to 142% of intact and 369% of 6-OHDA-lesioned rats. DSP4 (50 mg/kg) decreased NE (-97%), DOPAC (-75%) and DOPAC/DA ratio (-69%). Reserpine (5 mg/kg s.c.) significantly decreased DOPAC (-84%), DOPAC/DA ratio (-81%), 5-HT (-69%) and NE (-86%), but nonsignificantly increased DA. In the intact rats, MK-801 did not change DA, but increased DOPAC and DOPAC/DA ratio. In 6-OHDA-lesioned rats, MK-801 increased DA, whereas in 6-OHDA+DMI rats MK-801 additionally increased DOPAC and DOPAC/DA ratio. DSP4 and reserpine reduced the ability of MK-801 to increase DOPAC and DOPAC/DA ratio. MK-801 did not change NE concentration in dialysates collected from intact rats, but increased that from 6-OHDA+DMI-lesioned rats. In DSP4-lesioned and reserpine-treated rats, MK-801 increased NE but to a level lower than that observed in the intact rats. These results suggest that systemic administration of a low dose of MK-801, which induces profound locomotor stimulation without stereotypy, increases DOPAC and DOPAC/DA ratio in the cACC of intact rats, whereas it additionally increases the depleted DA and NE concentrations especially in 6-OHDA-lesioned rats pretreated with DMI.     

Differential visualization of dopamine and norepinephrine uptake sites in rat brain using [3H]mazindol autoradiography

Mazindol is a potent inhibitor of neuronal dopamine (DA) and norepinephrine (NE) uptake. DA and NE uptake sites in rat brain have been differentially visualized using [3H]mazindol autoradiography. At appropriate concentrations, desipramine (DMI) selectively inhibits [3H]mazindol binding to NE uptake sites without significantly affecting binding to DA uptake sites. The localization of DMI-insensitive specific [3H] mazindol binding, reflecting DA uptake sites, is densest in the caudate-putamen, the nucleus accumbens, the olfactory tubercle, the subthalamic nucleus, the ventral tegmental area, the substantia nigra (SN) pars compacta, and the anterior olfactory nuclei. In contrast, the localization of DMI-sensitive specific [3H]mazindol binding, representing NE uptake sites, is densest in the locus coeruleus, the nucleus of the solitary tract, the bed nucleus of the stria terminalis, the paraventricular and periventricular nuclei of the hypothalamus, and the anteroventral thalamus. The distribution of DMI-insensitive specific [3H]mazindol binding closely parallels that of dopaminergic terminal and somatodendritic regions, while the distribution of DMI-sensitive specific [3H]mazindol binding correlates well with the regional localization of noradrenergic terminals and cell bodies. Injection of 6-hydroxydopamine, ibotenic acid, or colchicine into the SN decreases [3H]mazindol binding to DA uptake sites in the ipsilateral caudate-putamen by 85%. In contrast, ibotenic acid lesions of the caudate-putamen do not reduce [3H]mazindol binding to either the ipsilateral or contralateral caudate-putamen. Thus, the DA uptake sites in the caudate-putamen are located on the presynaptic terminals of dopaminergic axons originating from the SN.